The overarching mission of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms (MPNs) is the clinical development of new and effective therapies for myeloproliferative neoplasms (MPNs) that will significantly improve the quality of life and the outcomes of our patients, extend survival, and ultimately cure MPNs. The Hanns Pielenz Center for MPNs is world-renowned for developing novel medications, such as the JAK1/2 inhibitor ruxolitinib, which dramatically improved the lives and extended survival of patients with myelofibrosis.
The main goals of the Hanns A. Pielenz Clinical Research Center for MPNs are to develop novel medications and therapeutic strategies to effectively treat MPNs, improve the patients' quality of life, extend survival, and provide exceptional patient care. Our efforts are focused on three key areas:
Clinical Research in MPNs
- Conduct clinical trials on novel agents developed for patients with MPNs. The Hanns A. Pielenz Clinical Research Center for MPNs provides the clinical infrastructure to conduct leading clinical research in MPNs. We are strongly committed to pursuing excellence in patient care and MPN research. For an overview of novel MPN medications that are in advanced clinical development and major recent advancements in treatments of MPNs, please visit the page "Current MPN Research".
Tissue Bank/Laboratory Research in MPNs
- The Hanns A. Pielenz Clinical Research Center for MPNs has established a centralized tissue bank for collection of patient samples for translational research and a database for clinical and pathology information. Our MPN tissue bank comprises specimens and clinical data (including bone marrow biopsies and mutations) for more than 2,500 patients. Besides conducting leading clinical research, we aim to understand the mechanism of bone marrow fibrosis (scarring), which underlies the design and clinical development of novel agents that may prevent progression of the disease.
Education and Awareness
- Disseminate information about MPNs and educate patients, families, healthcare providers, and the community at large about the latest MPN treatments and research strategies. We periodically publish the patient-centered newsletter MPN Focus. To read our MPN Focus newsletters, please visit the page "MPN Awareness and Education" . In the MPN Focus newsletters, we present all the active clinical trials evaluating emerging MPN medications at MD Anderson, and highlight the most important findings from MPN clinical research studies.
This is a very exciting time because many new medications are being developed to treat MPNs.
Srdan Verstovsek, MD, PhD, Professor of Medicine; Director of the Hanns A. Pielenz Clinical Research Center for MPNs